Medindia LOGIN REGISTER
Medindia
Advertisement

FDA Asks Johnson & Johnson To Stop Marketing Hip System

by Gopalan on August 27, 2010 at 11:29 AM
 FDA Asks Johnson & Johnson To Stop Marketing Hip System

The US Food and Drug Administration (FDA) has asked pharma giant Johnson & Johnson's DePuy Orthopaedics Inc to stop selling its Coral Hip System for unapproved uses and to provide information needed for the agency to approve the TruMatch software.

The FDA's warning letter, addressed to DePuy President David Floyd, was posted on the agency's website on Tuesday. The letter is dated Aug. 19. It is signed by Timothy A. Ulatowski, director of the Office of Compliance in the FDA center that oversees medical devices.

Advertisement

The FDA states that the Corail Hip System is approved for total hip replacement in patients with six specific types of damage to the hip. But a brochure on DePuy website claims the system can be used for treating two other conditions.

"Failure to promptly correct these violations may result in regulatory action being initiated by the Food and Drug Administration without further notice," the agency said in the letter. "These actions include, but are not limited to seizure, injunction, and or civil money penalties."
Advertisement

As for the TruMatch System, it uses software and high-tech CT scanning technology to create a detailed, 3-D view of a patient's knee so a surgeon can properly position a knee implant.

"A review of our records reveals that you have not obtained marketing approval or clearance before you began offering the TruMatch Personalized Solutions System for sale, which is a violation of the law," the FDA said in the letter.

"The FDA will evaluate the information you submit and decide whether your product may be legally marketed," stated the letter.

On Monday, Johnson & Johnson issued its ninth product recall in a year, this one covering millions of 1 Day Acuvue TruEye contact lenses sold in Japan and two dozen other countries in Asia and Europe. The recall followed complaints from customers in Japan of an unusual stinging or pain when inserting the lenses. Johnson & Johnson's Vision Care Inc. business blamed the failure of manufacturing equipment that rinses off substances used in producing the lenses, AP reports.

Johnson & Johnson already is under scrutiny by FDA officials, Congress and federal prosecutors over eight previous U.S. recalls of nonprescription medicines since last September. Those included millions of bottles of Tylenol, other pain relievers and cold medicines for children and adults.

The recalls have involved problems ranging from bacterial contamination and a nauseating smell on containers to drugs that may have the wrong amount of active ingredient and liquid medicines that may contain tiny metal shavings.

A DePuy Orthopaedics spokeswoman said Tuesday that the company has received the warning letter.

"We are reviewing the letter to understand the FDA's concerns and will respond to their request for information," she said by email.



Source: Medindia
Font : A-A+

Advertisement

Advertisement
Advertisement

Latest Corporate News

 Global Report of Work-related Diseases
The first World Health Organisation (WHO)/ International Labour Organisation (ILO) joint global monitoring report shows that more action is needed to ensure healthier, safer, more resilient, and more social workplaces.
New AI Tool Could Ensure Smooth Job Transitions
Successful career transitions could be possible when people leverage their existing skills in the new occupation. A new Artificial Intelligence tool helps employees figure out the right job according to their current skill set.
 Recent Improvements In Pharmaceutical Sector
AI and big data rule the pharmaceutical sector by enhancing the drug development process and increasing the marketing and sales of drugs
Food to be Covered by Insurance Soon
Insurance companies in the US are working towards adding food to their coverage menu to improve the people's health under their coverage and cut hospital costs.
Pharma Companies Have to Support or Risk Damaging Global Reputation
Pharmaceutical companies need to make strategic decisions that will provide financial benefit while showing strong commitment to global health and their patients during the pandemic.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

FDA Asks Johnson & Johnson To Stop Marketing Hip System Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests